<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>43(6)</volume><submitter>Li Q</submitter><pubmed_abstract>A number of emerging studies in field of immune metabolism have indicated that cellular metabolic reprograming serves as a major administrator in maintaining the viability and functions of both tumor cells and immune cells. As one of the most important immunosuppressive cells in tumor stroma, myeloid-derived suppressor cells (MDSCs) dynamically orchestrate their metabolic pathways in response to the complicated tumor microenvironment (TME), a process that consequently limits the therapeutic effectiveness of anti-cancer treatment modalities. In this context, the metabolic vulnerabilities of MDSCs could be exploited as a novel immune metabolic checkpoint upon which to intervene for promoting the efficacy of immunotherapy. Here, we have discussed about recent studies highlighting the importan</pubmed_abstract><journal>Acta pharmacologica Sinica</journal><pagination>1337-1348</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9160034</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.</pubmed_title><pmcid>PMC9160034</pmcid><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Xiang M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.</name><description>A number of emerging studies in field of immune metabolism have indicated that cellular metabolic reprograming serves as a major administrator in maintaining the viability and functions of both tumor cells and immune cells. As one of the most important immunosuppressive cells in tumor stroma, myeloid-derived suppressor cells (MDSCs) dynamically orchestrate their metabolic pathways in response to the complicated tumor microenvironment (TME), a process that consequently limits the therapeutic effectiveness of anti-cancer treatment modalities. In this context, the metabolic vulnerabilities of MDSCs could be exploited as a novel immune metabolic checkpoint upon which to intervene for promoting the efficacy of immunotherapy. Here, we have discussed about recent studies highlighting the importan</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-26T23:01:08.369Z</modification><creation>2025-04-06T17:24:18.836Z</creation></dates><accession>S-EPMC9160034</accession><cross_references><pubmed>34561553</pubmed><doi>10.1038/s41401-021-00776-4</doi></cross_references></HashMap>